Randomized, Double-Blind, Pilot Study Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction

Empagliflozin can not only decrease blood glucose levels, but also be used to treat heart failure (HF). 1 Packer M. Anker S.D. Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413-1424 Crossref PubMed Scopus (2146) Google Scholar ,2 Anker S.D. Butler J. Filippatos G. et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385: 1451-1461 Crossref PubMed Scopus (1397) Google Scholar A study suggested that empagliflozin 25 mg is preferable to 10 mg for patients with HF with reduced ejection fraction. 3 Hao Z. Zhang Y. Different doses of empagliflozin in patients with heart failure with reduced ejection fraction. Int Heart J. 2022; 63: 852-856 Crossref PubMed Scopus (2) Google Scholar However, it was unclear if there are differences in the effects of 10 mg and 25 mg of empagliflozin on the outcomes of patients with HF with preserved ejection fraction (HFpEF). The main aim of this study was to compare the efficacy of 10 mg and 25 mg of empagliflozin in patients with HFpEF. A Dose Comparison Study of Empagliflozin in Patients With Heart Failure With Preserved Ejection FractionCanadian Journal of CardiologyPreviewA trial recently published by Hao et al. 1 compared the effects of empagliflozin 10 mg vs 25 mg per day in 200 patients with heart failure (HF) with preserved ejection fraction (HFpEF) over 1 year. The authors found a statistically significant difference in favour of the 25-mg dose for the primary outcome of HF hospitalization or cardiovascular death (9% vs 19%; relative risk, 0.47). Full-Text PDF Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?Canadian Journal of CardiologyVol. 39Issue 5PreviewOver the past 40 years, we have observed the introduction of several medical therapies for heart failure (HF) with reduced ejection fraction (HFrEF). More recently, effective medical therapy (goal-directed medical therapy; GDMT) for patients who suffer from HF with preserved ejection fraction (HFpEF) has been identified in the form of sodium-glucose cotransporter 2 (SGLT2) inhibitors.1 There has also been recognition that timely and aggressive GDMT titration to target doses leads to better outcomes. Full-Text PDF